Producing Labeled Antigens Patents (Class 436/544)
  • Patent number: 10690683
    Abstract: The present disclosure relates to compounds and methods for labeling and/or detecting proteins in vivo, and methods for probing mitochondrial structure and/or dynamics.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: June 23, 2020
    Assignee: University of Conneticut
    Inventors: Royce Mohan, Paola Bargagna-Mohan, Dennis L. Wright, Santosh Keshipeddy
  • Patent number: 10663470
    Abstract: The invention provides a method of detecting the presence or absence of a disease in a patient wherein said disease is accompanied by deficient levels of S-adenosylmethionine comprising: identifying a patient that is suspected of having said disease or is at risk of having said disease; obtaining a biological sample from said patient; determining the level of S-adenosylmethionine in said biological sample using an antibody derived from a hapten analog of S-adenosylmethionine; and correlating the level of S-adenosylmethionine in said biological sample with the presence, absence, or severity of said disease. The invention also provides methods for measuring SAH which is used to determine the methylation index (ratio of SAM/SAH) in biological fluids which is indicative of the health status of an individual. Additionally, the invention includes test strips which are useful for determining S-adenosylmethionine and S-adenosylhomocysteine.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: May 26, 2020
    Assignee: HUNAN SKYWORLD BIOTECHNOLOGIES CO
    Inventors: Xiujuan Hao, Isaac Angres
  • Patent number: 9958447
    Abstract: The invention provides a method of detecting the presence or absence of a disease in a patient wherein said disease is accompanied by deficient levels of S-adenosylmethionine comprising: identifying a patient that is suspected of having said disease or is at risk of having said disease; obtaining a biological sample from said patient; determining the level of S-adenosylmethionine in said biological sample using an antibody derived from a hapten analog of S-adenosylmethionine; and correlating the level of S-adenosylmethionine in said biological sample with the presence, absence, or severity of said disease. The invention also provides methods for measuring SAH which is used to determine the methylation index (ratio of SAM/SAH) in biological fluids which is indicative of the health status of an individual. Additionally, the invention includes test strips which are useful for determining S-adenosylmethionine and S-adenosylhomocysteine.
    Type: Grant
    Filed: August 11, 2014
    Date of Patent: May 1, 2018
    Assignee: HUNAN SKYWORLD BIOTECHNOLOGIES CO
    Inventors: Xiujuan Hao, Isaac A Angres
  • Patent number: 9885723
    Abstract: The invention provides a method of detecting the presence, absence or severity of a disease in a patient wherein said disease is accompanied by decreased level of S-adenosylmethionine, or increased level of S-adenosylhomocysterine, or reduced methylation index comprising: identifying any individual or a patient that is suspected of having said disease or is at risk of having said disease; obtaining a biological sample from said patient; determining the level of SAM in said biological sample using an antibody derived from a hapten analog of SAM, SAH; and correlating the levels of SAM, SAH and MI in said biological sample with the presence, absence, or severity of said disease. The invention also provides methods for determining methylation index in biological fluids which is indicative of the health status of an individual. Additionally, the invention includes colloidal gold test strips and homogenous enzyme immunoassays which are useful for determining S-adenosylmethionine and S-adenosylhomocysteine.
    Type: Grant
    Filed: June 7, 2015
    Date of Patent: February 6, 2018
    Assignee: HUNAN SKYWORLD BIOTECHNOLOGIES CO
    Inventors: Xiujuan Hao, Isaac A Angres
  • Patent number: 9877982
    Abstract: A method of detecting the presence or absence of a disease in a patient wherein said disease is accompanied by deficient levels of S-adenosylmethionine comprising: identifying a patient that is suspected of having said disease or is at risk of having said disease; obtaining a biological sample from said patient; determining the level of S-adenosylmethionine in said biological sample using an antibody derived from a hapten analog of S-adenosylmethionine; and correlating the level of S-adenosylmethionine in said biological sample with the presence or absence of said disease. The invention also provides methods for measuring SAH which is used to determine the methylation index (ratio of SAM/SAH) in biological fluids which is indicative of the health status of an individual.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: January 30, 2018
    Assignee: Hunan SkyWorld Biotechnologies Co. LTD
    Inventors: Xiujuan Hao, Isaac A Angres
  • Patent number: 9579402
    Abstract: The present invention relates to fluorescent dyes in general. The present invention provides a wide range of fluorescent dyes and kits containing the same, which are applicable for labeling a variety of biomolecules, cells and microorganisms. The present invention also provides various methods of using the fluorescent dyes for research and development, forensic identification, environmental studies, diagnosis, prognosis, and/or treatment of disease conditions.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: February 28, 2017
    Assignee: Biotium, Inc.
    Inventors: Fei Mao, Wai-Yee Leung, Ching-Ying Cheung, Hye Eun Hoover
  • Patent number: 9250248
    Abstract: The present invention is based on the discovery that hexosamine, and in particular the dynamic O-GlcNAcylation of proteins (modification of proteins by the sugar N-acetylglucosamine) both causes insulin-resistance (a hallmark of type II diabetes) and is responsible for glucose toxicity in the disease. Accordingly, the invention provides methods of diagnosing a subject as having or at risk of having pre-diabetes or diabetes. Also provided are methods of characterizing hyperglycemia in a subject, methods of identifying a protein as being associated with hyperglycemia, and kits for detecting pre-diabetes or diabetes.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: February 2, 2016
    Assignee: The Johns Hopkins University
    Inventors: Gerald W. Hart, Kyoungsook Park, Christopher D. Saudek, Zihao Wang
  • Patent number: 9040310
    Abstract: Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly linked to an antibody or fragment thereof through a metal-thiol bond. Methods of making the antibody-nanoparticle conjugates disclosed herein include reacting an arylphosphine-nanoparticle composite with a reduced antibody to produce an antibody-nanoparticle conjugate. Also disclosed herein are methods for detecting a target molecule in a sample that include using an antibody-nanoparticle conjugate (such as the antibody-nanoparticle conjugates described herein) and kits for detecting target molecules utilizing the methods disclosed herein.
    Type: Grant
    Filed: April 27, 2011
    Date of Patent: May 26, 2015
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Julia Ashworth-Sharpe, Chol Steven Yun, Zhanna Zhilina, Adrian E. Murillo, Donald D. Johnson, Michael Farrell, Jerome W. Kosmeder, Christopher Bieniarz
  • Patent number: 9017954
    Abstract: Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: April 28, 2015
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Jerry W. Kosmeder, II, Casey A. Kernag, Donald Johnson, Christopher Bieniarz
  • Patent number: 9017957
    Abstract: An object of the present invention is to provide an antibody that can be stably supplied and can react with prostasin under non-denaturation and denaturation conditions, and an antigen peptide for preparation of the antibody. The present invention relates to a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a peptide consisting of an amino acid sequence that has a deletion, a substitution, or an addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1 and having antigenicity of prostasin. Furthermore, the present invention relates to an antibody prepared using the peptide as an antigen.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: April 28, 2015
    Assignees: Hitachi Chemical Company, Ltd., Kimio Tomita, Kenichiro Kitamura
    Inventors: Hiromi Iijima, Noriya Ohta, Kimio Tomita, Kenichiro Kitamura
  • Patent number: 9012241
    Abstract: In one embodiment, a system includes a plurality of metal nanoparticles functionalized with a plurality of organic molecules tethered thereto, wherein the plurality of organic molecules preferentially interact with one or more analytes when placed in proximity therewith. According to another embodiment, a method for detecting analytes includes contacting a fluid having one or more analytes of interest therein with a plurality of metal nanoparticles, each metal nanoparticle having a plurality of organic molecules tethered thereto, and detecting Raman scattering from an analyte of interest from the fluid, the analyte interacting with one or more of the plurality of organic molecules. In another embodiment, a method includes chemically modifying a plurality of cyclodextrin molecules at a primary hydroxyl moiety to create a chemical handle, and tethering the plurality of cyclodextrin molecules to a metal nanoparticle using the chemical handle. Other systems and methods for detecting analytes are also described.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: April 21, 2015
    Assignee: Lawrence Livermore National Security, LLC
    Inventors: Thomas Yong-Jin Han, Carlos A. Valdez, Tammy Y. Olson, Sung Ho Kim, Joe H. Satcher, Jr.
  • Patent number: 8999652
    Abstract: Mixtures of cell types can be analyzed by having at least two signal markers, with at least one at three different levels to provide a barcode for each cell type. The mixture of cells may be subjected to a common candidate moiety and the effect of the moiety on the cells determined along with identification of the cell by the barcode. Conveniently, surface marker proteins and labeled antibodies can be used to create the barcode and the cells analyzed with flow cytometry.
    Type: Grant
    Filed: August 5, 2008
    Date of Patent: April 7, 2015
    Assignee: Primity Bio, Inc.
    Inventors: Peter Oliver Krutzik, Thomas Scott Wehrman
  • Patent number: 8940546
    Abstract: Disclosed herein are isobaric labeling reagent sets useful for multiplexed quantitation of peptides. The isobaric labeling reagent sets include a collection of at least two isobaric labeling reagents having first and second reporter groups with the same nominal mass but different isotopic substitutions and consequently different exact masses. Mass spectrometric analysis of the labeled samples is performed using a mass analyzer, such as an Orbitrap mass analyzer, capable of adequately resolving the ions of the first and second reporter groups. Reagent sets of the foregoing description may provide a degree of multiplexing in reporter ion quantitation experiments that is expanded relative to conventional labeling reagent sets, thereby reducing the number of chromatographic runs required for analysis and improving sample throughput.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: January 27, 2015
    Assignee: Thermo Finnigan LLC
    Inventors: Robert A. Grothe, Jr., Justin Blethrow
  • Patent number: 8932881
    Abstract: New chemiluminescent compounds, stable in aqueous buffers, for use in biological assaying include acridane-based compounds and 1,2-dioxetanes. Among the new acridane-based compounds are water-soluble acridanes, enhancer coupled acridanes, bis and tris-acridanes as well as acridane-1,2-dioxetanes. Among the new 1,2-dioxetanes are electron deficient group-containing dioxetanes and tethered bis-1,2-dioxetanes. The 1,2-dioxetanes are useful as substrates for various enzymes. The acridanes can be admixed with an oxidizing agent, an aqueous buffer and, optionally, a stabilizer to form a substrate or reagent formulation useful for assaying, inter alia, HRP.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: January 13, 2015
    Inventors: Brij Pal Giri, Dinesh Dagli, Pritam Singh
  • Patent number: 8927290
    Abstract: Provided herein are compositions comprising native and denatured human leukocyte antigens (HLA) and methods of making said compositions. Also provided herein are methods and kits for the detection of antibodies to native HLAs.
    Type: Grant
    Filed: February 16, 2011
    Date of Patent: January 6, 2015
    Assignee: One Lambda, Inc.
    Inventors: Adam Idica, Chun-Tsan Deng, Paul I. Terasaki
  • Patent number: 8927300
    Abstract: The invention provides methods and compositions for the rapid and sensitive detection of post-translationally modified proteins, and particularly of those with posttranslational glycosylations. The methods can be used to detect O-GlcNAc posttranslational modifications on proteins on which such modifications were undetectable using other techniques. In one embodiment, the method exploits the ability of an engine˜red mutant of ?-1,4-galactosyltransferase to selectively transfer an unnatural ketone functionality onto O-GlcNAc glycosylated proteins. Once transferred, the ketone moiety serves as a versatile handle for the attachment of biotin, thereby enabling detection of the modified protein. The approach permits the rapid visualization of proteins that are at the limits of detection using traditional methods. Further, the preferred embodiments can be used for detection of certain disease states, such as cancer, Alzheimer's disease, neurodegeneration, cardiovascular disease, and diabetes.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: January 6, 2015
    Assignee: California Institute of Technology
    Inventors: Linda Hsieh-Wilson, Nelly Khidekel, Hwan-Ching Tai, Sabine Arndt
  • Patent number: 8889102
    Abstract: The present invention provides for methods and materials for diagnosing and treating neuromyelitis optica (NMO).
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: November 18, 2014
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Vanda A. Lennon, Sean J. Pittock
  • Patent number: 8889430
    Abstract: A nanostructure and methods of synthesizing same. In one embodiment, the nanostructure includes a magnetic iron oxide nanoparticle, a hydrophobic protection structure including at least an amphiphilic copolymer, wherein the hydrophobic protection structure encapsulates the magnetic iron oxide nanoparticle, and at least one amino-terminal fragment (ATF) peptide or epidermal growth factor receptor (EGFR) antibody conjugated to the amphiphilic copolymer.
    Type: Grant
    Filed: May 4, 2007
    Date of Patent: November 18, 2014
    Assignee: Emory University
    Inventors: Lily Yang, Hui Mao, Shuming Nie, Xiaohu Gao
  • Patent number: 8846320
    Abstract: A method for performing a multiplexed diagnostic assay, such as for two or more different targets in a sample, is described. One embodiment comprised contacting the sample with two or more specific binding moieties that bind specifically to two or more different targets. The two or more specific binding moieties are conjugated to different haptens, and at least one of the haptens is an oxazole, a pyrazole, a thiazole, a nitroaryl compound other than dinitrophenyl, a benzofurazan, a triterpene, a urea, a thiourea, a rotenoid, a coumarin, a cyclolignan, a heterobiaryl, an azo aryl, or a benzodiazepine. The sample is contacted with two or more different anti-hapten antibodies that can be detected separately. The two or more different anti-hapten antibodies may be conjugated to different detectable labels.
    Type: Grant
    Filed: February 17, 2010
    Date of Patent: September 30, 2014
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Jerome W. Kosmeder, Mark Lefever, Donald Johnson, Michael Farrell, Zhanna Zhilina, Christopher Bieniarz
  • Patent number: 8835186
    Abstract: The present invention relates to methods, compositions and kits for affinity isolation, affinity purification and affinity assay based on microbubbles coated with an affinity molecule. Particularly, the invention provides protein microbubbles coated with an affinity molecule. In addition, the invention provides glass microbubbles coated with an affinity molecule. Methods of using the microbubbles of the invention for isolating analytes and cells are specifically provided.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: September 16, 2014
    Assignee: Iris International, Inc.
    Inventors: Edward Jablonski, Thomas Adams
  • Patent number: 8835125
    Abstract: Disclosed are compositions and methods for the labeling of two or more targets with different labels. Specifically, disclosed are compositions for biotin and the protection of biotin within multilabel assays which employ the biotin-biotin binding protein binding relationship for each distinct label in relation to targets such as nucleic acids, polypeptides, antibodies or cells. These multilabel assays are enabled through the use of biotin with desthiobiotin, orthogonal protecting schemes for biotin, or a combination of the approaches.
    Type: Grant
    Filed: December 16, 2011
    Date of Patent: September 16, 2014
    Assignee: Affymetrix, Inc.
    Inventors: Robert G. Kuimelis, Glenn H. McGall, Stephen P. A. Fodor
  • Patent number: 8796429
    Abstract: Compositions and methods for producing monoclonal antibodies and their derivatives reactive against bioactive lipid targets are described. These compositions include derivatized lipids, each of which comprises a bioactive lipid that having a polar head group and at least one hydrocarbon chain (e.g., a lysolipid such as lysophosphatidic acid or sphingosine-1-phosphate) in which a carbon atom has been derivatized with a pendant reactive group; immunogens made by linking a derivatized lipid to a carrier moiety (e.g., a carrier protein, polyethylene glycol, colloidal gold, alginate, or a silicone bead); monoclonal antibodies and derivatives produced by immunizing an animal with such an immunogen; and therapeutic and diagnostic compositions containing such antibodies and antibody derivatives.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: August 5, 2014
    Assignee: Lpath, Inc.
    Inventors: Roger A. Sabbadini, William A. Garland, Genevieve Hansen
  • Patent number: 8785212
    Abstract: The present invention generally relates to methods of functionalizing proteins, particularly antibodies, at oligosaccharide linkages, methods of humanizing antibodies by modifying glycosylation, as well as to novel antibodies linked to modified oligosaccharides. The invention further relates to kits that may be used to produce the antibodies of the invention.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: July 22, 2014
    Assignee: Life Technologies Corporation
    Inventors: Brian Agnew, Kyle Gee, Schuyler Corry
  • Patent number: 8778624
    Abstract: Hydrophilic, chemiluminescent acridinium compounds containing zwitterions are disclosed. These acridinium compounds, when used as chemiluminescent labels in immunochemistry assays and the like, exhibit decreased non-specific binding to solid phases and provide increased assay sensitivity.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: July 15, 2014
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Anand Natrajan, David Sharpe, Qingping Jiang
  • Patent number: 8772048
    Abstract: Fluorophores derived from photoactivatable azide-pi-acceptor fluorogens or from a thermal reaction of an azide-pi-acceptor fluorogen with an alkene or alkyne are disclosed. Fluorophores derived from a thermal reaction of an alkyne-pi-acceptor fluorogen with an azide are also disclosed. The fluorophores can readily be activated by light and can be used to label a biomolecule and imaged on a single-molecule level in living cells.
    Type: Grant
    Filed: March 1, 2012
    Date of Patent: July 8, 2014
    Assignees: Kent State University, Leland Stanford Junior University
    Inventors: Robert J. Twieg, William E. Moerner, Samuel J. Lord, Na Liu, Reichel Samuel
  • Patent number: 8765384
    Abstract: A novel ligand conjugate which is effectively utilizable for analyzing a function of a protein; a ligand-supporting object; and a method of analyzing a protein. The ligand conjugate has a structure which comprises: a linker compound having a structure represented by the following General Formula (1): (wherein n and p each is an integer of 0 to 6) in which X is a structure comprising one, two, or three hydrocarbon derivative chains which have an aromatic amino group at the end and may have a carbon-nitrogen bond in the main chain, Y is a hydro-carbon structure containing one or more sulfur atoms, and Z is a straight-chain structure comprising a carbon-carbon bond or carbon-oxygen bond; and a sugar which has a reducing end and is bonded to the linker compound through the aromatic amino group.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: July 1, 2014
    Assignees: Japan Science and Technology Agency, National University Corporation Kagoshima University
    Inventor: Yasuo Suda
  • Patent number: 8735556
    Abstract: The invention relates to the detection and quantification of carbamazepine drugs and their metabolites. The invention is underpinned by novel polyclonal antibodies with unique binding properties which enable immunoassay methods and kits for various applications.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: May 27, 2014
    Assignee: Randox Laboratories Limited
    Inventors: Elouard Benchikh, Andrew Philip Lowry, Ivan McConnell, Peter Stephen Fitzgerald
  • Patent number: 8735178
    Abstract: Novel withanolide chemical genetic probes identify the in vivo binding target of withaferin A, which is the intermediate filament type III protein vimentin. In addition, a withanolide-based small molecule screening method screens drug candidates that target intermediate filament type III proteins. The method includes introducing a tagged linker covalently bonded to the withanolide molecule to form a withanolide probe. Better or alternative small molecule compounds as potential drug candidates can be generated based on their likely affinity for the determined binding site in vimentin. The affinity labeled withanolide can also be used to find intermediate filament-associated proteins using chemical proteomics by extracting proteins from cells that were exposed to withanolide-biotin analog. The withanolide probes can be used to monitor expression of vimentin, in tumor samples or other diseased tissues.
    Type: Grant
    Filed: February 14, 2007
    Date of Patent: May 27, 2014
    Assignee: University of Kentucky Research Foundation
    Inventors: Royce Mohan, Paola Bargagna-Mohan, Kyung Bo Kim
  • Patent number: 8716033
    Abstract: The present invention generally relates to methods of functionalizing proteins, particularly antibodies, at oligosaccharide linkages, methods of humanizing antibodies by modifying glycosylation, as well as to novel antibodies linked to modified oligosaccharides. The invention further relates to kits that may be used to produce the antibodies of the invention.
    Type: Grant
    Filed: February 12, 2007
    Date of Patent: May 6, 2014
    Assignee: Life Technologies Corporation
    Inventors: Brian Agnew, Schuyler B. Corry, Kyle R. Gee
  • Patent number: 8709830
    Abstract: The present invention provides methods, compositions, and kits useful in preparing labeled molecules, which are useful in the detection of binding partners.
    Type: Grant
    Filed: March 16, 2012
    Date of Patent: April 29, 2014
    Assignee: Biotium, Inc.
    Inventors: Fei Mao, Wai-Yee Leung, Ching-Ying Cheung, Hye Eun Hoover
  • Patent number: 8685752
    Abstract: The invention relates to a method for diagnosing a disease state mediated by pathogenic cells. The method comprises the steps of combining with an ex vivo patient sample a composition comprising a conjugate or complex of the general formula Ab-X, wherein the group Ab comprises a ligand that binds to the pathogenic cells and the group X comprises an imaging agent, and detecting the pathogenic cells that express a receptor for the ligand using flow cytometry.
    Type: Grant
    Filed: November 2, 2007
    Date of Patent: April 1, 2014
    Assignee: Purdue Research Foundation
    Inventors: Philip Stewart Low, Wei He, Sumith A Kularatne
  • Patent number: 8685662
    Abstract: The present invention pertains to a method for in vitro prognosticating and/or diagnosing cerebral cerebral malaria, wherein said method comprises a step of detecting non-erythroid spectrin or fragments thereof, and/or antibodies directed against non-erythroid spectrin, in a biological sample. Reagents and kits for performing this method are also disclosed.
    Type: Grant
    Filed: March 30, 2007
    Date of Patent: April 1, 2014
    Assignees: Institut Pasteur, Universite Pierre et Marie Curie (Paris 6)
    Inventors: Sylviane Pied, Vincent Guiyedi, Pierre-André Cazenave, Maryvonne Kombila, Youri Chanseaud
  • Patent number: 8686122
    Abstract: A method is disclosed for making a conjugate of two molecules using a hydrazide thiol linker. In a particular working embodiment, an Fc-specific antibody-enzyme conjugate is made using the method and demonstrated to provide exceptional staining sensitivity and specificity in immunohistochemical and in situ hybridization assays.
    Type: Grant
    Filed: January 14, 2010
    Date of Patent: April 1, 2014
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Julia Ashworth-Sharpe, Casey A. Kernag, Jerome W. Kosmeder, Mark Lefever
  • Patent number: 8658389
    Abstract: Antibody/signal-generating moiety conjugates are disclosed that include an antibody covalently linked to a signal-generating moiety through a heterobifunctional polyalkyleneglycol linker. The disclosed conjugates show exceptional signal-generation in immunohistochemical and in situ hybridization assays on tissue sections and cytology samples. In one embodiment, enzyme-metallographic detection of nucleic acid sequences with hapten-labeled probes can be accomplished using the disclosed conjugates as a primary antibody without amplification.
    Type: Grant
    Filed: March 13, 2009
    Date of Patent: February 25, 2014
    Assignee: Ventana Medical Systems, Inc.
    Inventors: Christopher Bieniarz, Jennifer Wong, Mark Lefever, Jerome W. Kosmeder, II, Julia Ashworth-Sharpe, Casey A. Kernag
  • Patent number: 8658433
    Abstract: Novel azo, azide, and sulfenate photoactive compounds and methods using the compounds for photodiagnostic and/or phototherapeutic procedures. The compounds have the formula E-L-DYE-X—Y, wherein DYE is a photoactive component comprising a photoactive diagnostic agent, a photoactive type 1 agent, a photoactive type 2 agent, or a combination thereof; Y is a photoactive component comprising a photoactive type 1 agent, a photoactive type 2 agent, or a combination thereof; E is a targeting component for targeting the compound to an anatomical and/or physiological site of a patient; L is a linking component for linking E to DYE; and X is a linking component for linking DYE to Y.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: February 25, 2014
    Assignee: Mallinckrodt LLC
    Inventors: Raghavan Rajagopalan, Gary L. Cantrell, Samuel I. Achilefu, Joseph E. Bugaj, Richard B. Dorshow
  • Patent number: 8658434
    Abstract: The present invention relates to fluorescent pyrene dyes in general. The present invention provides a wide range of fluorescent dyes and kits containing the same, which are applicable for labeling a variety of biomolecules, cells and microorganisms. The present invention also provides various methods of using the fluorescent dyes for research and development, forensic identification, environmental studies, diagnosis, prognosis, and/or treatment of disease conditions.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: February 25, 2014
    Assignee: Biotium, Inc.
    Inventors: Fei Mao, Wai-Yee Leung, Ching-Ying Cheung
  • Patent number: 8642357
    Abstract: The present invention provides methods of treating a subject diagnosed with, or at risk for developing, pathogenic fibrosis, particularly pulmonary fibrosis. The method of the invention comprises administering to the subject a compound or composition which inhibits semaphorin (SEMA) 7A, SEMA 7A receptors, or downstream effectors. A SEMA 7A inhibitor comprises an antibody, a soluble SEMA 7A receptor, an siRNA, a ribozyme, an antisense, an aptamer, a peptidomimetic, a small molecule, a soluble receptor, or any combinations thereof.
    Type: Grant
    Filed: October 22, 2009
    Date of Patent: February 4, 2014
    Assignee: Yale University
    Inventors: Jack A. Elias, Chun Geun Lee
  • Patent number: 8617824
    Abstract: A rapid and sensitive analyte detection assay is based on whispering gallery modes of fluorescently labelled microspheroidal particles. Ligands for the analyte, such as nucleic acids, are anchored to the particles. The fluorescent labels may comprise fluorophores or quantum dots. In the latter case, the particles may comprise melamine formaldehyde. The assay may be used to detect analytes in aqueous samples.
    Type: Grant
    Filed: November 20, 2009
    Date of Patent: December 31, 2013
    Assignees: Genera Biosystems Limited, The University of Melbourne
    Inventors: Karl Frederick Poetter, Edin Nuhiji, Paul Mulvaney
  • Patent number: 8614103
    Abstract: The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, particularly ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation, and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against the bioactive lipid, sphingosine-1-phosphate, and its variants, which moieties are capable of decreasing the effective concentration of bioactive lipid being targeted. In one embodiment, the immune-derived moiety is a humanized monoclonal antibody that is reactive against sphingosine-1-phosphate.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: December 24, 2013
    Assignee: Lpath, Inc.
    Inventors: Roger A. Sabbadini, William A. Garland, Glenn L. Stoller
  • Patent number: 8580579
    Abstract: The invention relates to novel and improved photostable rhodamine dyes of the general structural formulae I or II and their uses as fluorescent markers, e.g. for immunostainings and spectroscopic and microscopic applications, in particular in conventional and stimulated emission depletion (STED) microscopy and fluorescence correlation spectroscopy.
    Type: Grant
    Filed: April 26, 2010
    Date of Patent: November 12, 2013
    Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
    Inventors: Stefan Hell, Vladimir N. Belov, Kirill Kolmakov, Volker Westphal, Marcel Lauterbach, Stefan Jakobs, Christian Wurm, Christian Eggeling, Christian Ringemann
  • Patent number: 8568991
    Abstract: Methods comprising the use of photoactivated chemical bleaching for detecting multiple targets in a biological sample are provided. The methods include the steps of providing a biological sample containing multiple targets, binding at least one probe to one or more target present in the sample, and observing a signal from the probe. The method further includes the steps of contacting the sample comprising the bound probe with an electron transfer reagent and irradiating the sample, thereby initiating a photoreaction that substantially inactivates the probe by photoactivated chemical bleaching. The method further includes the steps of binding at least one probe to one or more target present in the sample, and observing a signal from the probe. The process of binding, observing and bleaching may be iteratively repeated.
    Type: Grant
    Filed: December 23, 2011
    Date of Patent: October 29, 2013
    Assignee: General Electric Company
    Inventors: Arunkumar Natarajan, Anup Sood, Lakshmi Sireesha Kaanumalle, Kwok Pong Chan
  • Patent number: 8535948
    Abstract: The invention provides improved crosslinkers which permit more efficient determination of protein interactions in biological samples.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: September 17, 2013
    Assignee: Institute for Systems Biology
    Inventors: Jeff Ranish, Jie Luo
  • Patent number: 8524508
    Abstract: The present invention provides for methods and materials for diagnosing and treating neuromyelitis optica (NMO).
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: September 3, 2013
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Vanda A. Lennon, Thomas J Kryzer
  • Patent number: 8518710
    Abstract: The present invention provides a method for reducing undesirable light emission from a sample using at least one photon producing agent and at least one photon reducing agent (e.g. dye-based photon reducing agents). The present invention further provides a method for reducing undesirable light emission from a sample (e.g., a biochemical or cellular sample) with at least one photon producing agent and at least one collisional quencher. The present invention also provides a method for reducing undesirable light emission from a sample (e.g., a biochemical or cellular sample) with at least one photon producing agent and at least one quencher, such as an electronic quencher. The present invention also provides a system and method of screening test chemicals in fluorescent assays using photon reducing agents. The present invention also provides compositions, pharmaceutical compositions, and kits for practicing these methods.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: August 27, 2013
    Assignee: Life Technologies Corporation
    Inventors: Tom Knapp, Gregory Zlokarnik, Paul Negulescu, Roger Tsien, Timothy Rink
  • Patent number: 8518715
    Abstract: A bifunctional polyazamacrocyclic chelating agent of the formula (I): wherein: and the variables A, L, Q, Q1, X, Y, Z, Z1, m, n and r are as defined in the description of the present application. Also described is a complex of the above chelating agent to an ion of a metal ion, such as an ion of 90Y, 111In or 177Lu; a conjugate of the complex covalently attached to a biological carrier; and a pharmaceutical composition containing the conjugate. A method of therapeutic treatment of a mammal involving administration of the pharmaceutical composition is also described.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: August 27, 2013
    Assignee: Nordion (Canada) Inc.
    Inventors: Zoltan Kovacs, Garry E. Kiefer, Corinne Bensimon, A. Dean Sherry, Gyula Tircso, Cara Ferreira
  • Patent number: 8513032
    Abstract: The present invention relates to methods, compositions and kits for affinity isolation, affinity purification and affinity assay based on microbubbles coated with an affinity molecule. Particularly, the invention provides protein microbubbles coated with an affinity molecule. In addition, the invention provides glass microbubbles coated with an affinity molecule. Methods of using the microbubbles of the invention for isolating analytes and cells are specifically provided.
    Type: Grant
    Filed: May 31, 2011
    Date of Patent: August 20, 2013
    Assignee: Iris International, Inc.
    Inventors: Edward Jablonski, Thomas Adams
  • Patent number: 8507214
    Abstract: The present invention provides an ELISA kit for detecting lincomycin comprising a coating antigen and an enzyme labeled reagent, wherein the coating antigen is selected from the group consisting of a lincomycin hapten-carrier protein conjugate, a lincomycin antibody and a lincomycin anti-antibody; when the coating antigen is the lincomycin hapten-carrier protein conjugate, the enzyme labeled reagent is an enzyme-labeled lincomycin anti-antibody; when the coating antigen is the lincomycin antibody, the enzyme labeled reagent is an enzyme-labeled lincomycin hapten-carrier protein conjugate; and when the coating antigen is the lincomycin anti-antibody, the enzyme labeled reagent is an enzyme-labeled lincomycin hapten-carrier protein conjugate; and the lincomycin hapten is obtained through the condensation reaction between lincomycin and succinic anhydride.
    Type: Grant
    Filed: September 27, 2008
    Date of Patent: August 13, 2013
    Assignee: Beijing Kwinbon Biotechnology Co., Ltd.
    Inventors: Fangyang He, Yuping Wan, Caiwei Feng, Zhengmiao Zhao, Caimao Feng, Shanliang Wang, Xiaoqin Luo, Xiaobin Ma
  • Patent number: 8501498
    Abstract: This invention pertains to methods, mixtures, kits and/or compositions for the determination of analytes by mass analysis using unique labeling reagents or sets of unique labeling reagents. The labeling reagents can be isomeric or isobaric and can be used to produce mixtures suitable for multiplex analysis of the labeled analytes.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: August 6, 2013
    Assignee: DH Technologies Development Pte. Ltd.
    Inventors: Xiongwei Yan, Pau-Miau Yuan, Sylvia W. Yuen, Kuo-Liang Hsi, Joe Y. Lam, Krishna G. Upadhya, Subhakar Dey, Darryl J. C. Pappin, Sasi Pillai, Helena Huang, Subhasish Purkayastha
  • Patent number: 8486401
    Abstract: Monoclonal antibodies, synthetic and biotechnological derivatives thereof (ScFv or others) are able to recognise the NGF high affinity receptor, TrkA, and act as NGF-antagonist molecules. Pharmacological compositions for therapy, gene therapy, diagnostics of neurological pathologies are also described. Transgenic animal models to study such pathologies are also described.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: July 16, 2013
    Assignee: Lay Line Genomics S.p.A.
    Inventor: Michal M. Novak
  • Patent number: RE45272
    Abstract: Ligand Drug conjugate compounds comprising a ?-glucuronide-based linker and methods of using such compounds are provided.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: December 2, 2014
    Assignee: Seattle Genetics, Inc.
    Inventor: Scott Jeffrey